Treatment of venous thromboembolism in Northern Italy: A population-based study from 2013 to 2018

The standard of care for venous thromboembolism (VTE) includes initial treatment with heparin followed by vitamin K antagonists (VKAs) [1]. Over the past decade, non-vitamin K antagonists (NOACs) have been compared with initial low-molecular-weight heparin (LMWH) followed by long-term VKA treatment; they have proved non-inferior for recurrent VTE, with a lower risk of major bleeding [2]. NOACs are recommended by the 2016 American College of Chest Physicians and 2017 European Society of Cardiology guidelines for deep venous thrombosis (DVT) and pulmonary embolism (PE).
Source: Thrombosis Research - Category: Hematology Authors: Tags: Letter to the Editors-in-Chief Source Type: research